OR
$81.15
+1.23
(+1.54%)
As of Oct 22, 2026, 9:33 PM EDT
Price history
Oruka Therapeutics Inc (ORKA) is trading up at $81.15 (+1.54%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Oruka Therapeutics Inc revenue & net income history (FY2015–FY2025)
RevenueNet income
| FY2015Dec 2015 | FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Operating income | −$11.5M | −$16.6M | −$18.7M | −$8.12M | −$5.81M | −$9.77M | −$19.3M | −$10.6M | −$7.30M | −$122.1M |
| Net income | −$11.4M | −$16.4M | −$18.5M | −$7.93M | −$5.48M | −$9.74M | −$19.3M | −$9.93M | −$5.34M | −$105.4M |
| EPS (diluted) | −$1.82 | −$1.81 | −$1.77 | −$10.31 | −$4.15 | −$2.07 | −$1.39 | −$0.69 | −$0.37 | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $38.8M | $7.40M | $8.70M | $6.61M | $8.36M | $49.1M | $53.4M | $42.4M | $37.4M | $46.9M |
| Total assets | $39.6M | $24.6M | $12.4M | $6.83M | $8.54M | $50.4M | $54.9M | $43.1M | $37.9M | $488.6M |
| Total liabilities | $1.50M | $2.44M | $2.09M | $793.0K | $926.0K | $3.91M | $3.88M | $1.41M | $841.0K | $16.7M |
| Shareholders' equity | $38.1M | $22.2M | $10.3M | $6.03M | $7.61M | $46.5M | $51.0M | $41.7M | $37.0M | $471.9M |
| Cash flow | ||||||||||
| Operating cash flow | −$10.5M | −$15.0M | −$17.5M | −$8.24M | −$4.80M | −$7.72M | −$18.8M | −$10.9M | −$5.01M | −$88.2M |
| Capital expenditure | $11.0K | $12.0K | $3.00K | $4.00K | $4.00K | $19.0K | $43.0K | $2.00K | $0 | $209.0K |
| Free cash flow | −$10.5M | −$15.0M | −$17.5M | −$8.25M | −$4.80M | −$7.74M | −$18.8M | −$10.9M | −$5.01M | −$88.4M |
RevenueNet income
| Q3 FY23†Sep 2023 | Q4 FY23Dec 2023 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Operating income | −$1.94M | — | −$25.1M | −$28.4M | −$34.1M | −$34.4M | −$36.4M | −$50.1M |
| Net income | −$1.42M | — | −$21.0M | −$24.6M | −$30.3M | −$29.6M | −$31.8M | −$41.2M |
| EPS (diluted) | −$0.10 | — | −$0.40 | −$0.46 | — | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $38.5M | $37.4M | $83.6M | $65.4M | $91.3M | $46.9M | $49.5M | $268.5M |
| Total assets | $39.2M | $37.9M | $377.1M | $357.4M | $509.3M | $488.6M | $504.5M | $1.14B |
| Total liabilities | $1.22M | $841.0K | $12.4M | $13.8M | $22.5M | $16.7M | $17.8M | $24.8M |
| Shareholders' equity | $38.0M | $37.0M | $364.7M | $343.6M | $486.8M | $471.9M | $486.7M | $1.11B |
| Cash flow | ||||||||
| Operating cash flow | −$1.67M | — | −$20.9M | −$23.1M | −$21.6M | −$22.6M | −$23.6M | −$33.1M |
| Capital expenditure | — | — | $13.0K | $34.0K | $99.0K | $63.0K | $73.0K | $0 |
| Free cash flow | — | — | −$20.9M | −$23.2M | −$21.7M | −$22.7M | −$23.7M | −$33.1M |
From Oruka Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Oruka Therapeutics Inc
- Headquarters
- Menlo Park, California From SEC filings, Oct 2026
Recent News (4)
-
Oruka Therapeutics general counsel sells $706k in shares
Oruka Therapeutics general counsel sells $706k in shares
-
Oruka Therapeutics CMO Joana Goncalves sells $523,647 in stock
Oruka Therapeutics CMO Joana Goncalves sells $523,647 in stock
-
Oruka Therapeutics senior vice president Arjun Agarwal sells $805,888 in stock
Oruka Therapeutics senior vice president Arjun Agarwal sells $805,888 in stock
-
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new stan…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International